Nirsevimab (MEDI8897) is a recombinant human respiratory syncytial virus (RSV research[1][2][3].
[1]. Griffin MP, et al. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N Engl J Med. 2020 Jul 30;383(5):415-425.
[2]. Griffin MP, et al. Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healt Adults. Antimicrob Agents Chemother. 2017 Feb 23;61(3):e01714-16.
[3]. CabÁn M, et al. Cross-protective antibodies against common endemic respiratory viruses. Nat Commun. 2023 Feb 13;14(1):798.
















